Table 2.
Odds ratio of ACPA-positive RA, ACPA-negative RA and RA overall according to ever, current and past use of PMH among women aged 50–70
| ACPA status | Use of PMH | Ca/Co | OR 95 % CIa | OR 95 % CIb |
|---|---|---|---|---|
| ACPA-positive | Everc | 90/304 | 0.9 (0.7–1.2) | 0.9 (0.6–1.2) |
| Current | 22/105 | 0.6 (0.4–1.0) | 0.6 (0.3–0.9) | |
| Past | 68/197 | 1.0 (0.7–1.4) | 1.1 (0.8–1.5) | |
| Never | 209/626 | 1.0 | 1.0 | |
| Missingd | 4/5 | – | – | |
| ACPA-negative | Ever | 55/304 | 1.1 (0.7–1.5) | 1.0 (0.7–1.4) |
| Current | 18/105 | 1.0 (0.6–1.7) | 0.9 (0.5–1.5) | |
| Past | 37/197 | 1.1 (0.7–1.7) | 1.1 (0.7–1.7) | |
| Never | 109/626 | 1.0 | 1.0 | |
| Missingd | 0/5 | – | – | |
| RA overall | Ever | 145/304 | 0.9 (0.7–1.2) | 0.9 (0.7–1.2) |
| Current | 40/105 | 0.7 (0.5–1.1) | 0.7 (0.4–1.0) | |
| Past | 105/197 | 1.1 (0.8–1.4) | 1.1 (0.8–1.4) | |
| Never | 318/626 | 1.0 | 1.0 | |
| Missingd | 4/5 | – | – |
EIRA, Sweden, 2006–2011
ACPA antibodies to citrullinated peptides antigens, PMH postmenopausal hormone, RA rheumatoid arthritis, Ca/Co number of cases/controls, OR odds ratio, CI confidence interval
aAdjusted by age and residential area
bAdjusted by age, residential area and smoking (pack-years)
cTwo controls had only information on year of initiation and type of therapy and they were defined as ever users
dMissing information on PMH use